Bisphosphonate-related Osteonecrosis of the Jaws: An Update on Clinical, Pathological and Management Aspects

Head and Neck Pathology

Volumn 1, Issue 2, 2007, Pages 132-140

  Ficarra, Giuseppe ^a,b   Beninati, Francesco ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

Bisphosphonate; Bone metastasis; Cancer; Jaws; Osteomyelitis; Osteonecrosis; Osteoporosis; Pamidronate; Review; Zoledronic acid

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE; PAMIDRONIC ACID; ZOLEDRONIC ACID;

BONE NECROSIS; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; JAW DISEASE; MANDIBLE; ORAL DRUG ADMINISTRATION; PATHOLOGY; RETROSPECTIVE STUDY; REVIEW;

ADMINISTRATION, ORAL; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; HUMANS; IMIDAZOLES; INJECTIONS, INTRAVENOUS; JAW DISEASES; MANDIBLE; OSTEONECROSIS; RETROSPECTIVE STUDIES;

EID: 77957108663     PISSN: 1936055X     EISSN: 19360568     Source Type: Journal    
DOI: 10.1007/s12105-007-0033-2     Document Type: Review

References (64)

1. Wu S, Dahut WL, Gulley JL. The use of bisphosphonates in cancer patients. Acta Oncol 2007;46:581-91
2. Wang J, Goodger NM, Pogrel MA. Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg 2003;61:1104-7
3. Rosenberg TJ, Ruggiero S. Osteonecrosis of the jaws associated with the use of bisphosphonates. J Oral Maxillofac Surg 2003;61:60 (letter)
4. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003; 61:1115-7 (letter)
5. Migliorati CA. Bisphosphonates and oral cavity avascular bone necrosis. New Engl J Med 2003;21:4253-4 (letter)
6. Ruggiero SL, Mehrotra B, Rosenberg TJ, et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004;62:527-34
7. Lugassy G, Shaham R, Nemets A, et al. Severe osteomyelitis of the jaw in long-term survivors of multiple myeloma: a new clinical entity. Am J Med 2004;117:440-1
8. Bagan JV, Murillo J, Poveda R, et al. Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases. J Oral Pathol Med 2005;34:120-3
9. Vannucchi AM, Ficarra G, Antonioli E, et al. Osteonecrosis of the jaw associated with zoledronate therapy in a patient with multiple myeloma. Br J Haematol 2005;128:738 (letter)
10. Ficarra G, Beninati F, Rubino I, et al. Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment. J Clin Periodontol 2005;32:1123-8
11. Migliorati CA, Schubert MM, Peterson DE, et al. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer 2005;104:83-93
12. Merigo E, Manfredi M, Meleti M, et al. Jaw bone necrosis without previous dental extractions associated with the use of bisphosphonates (pamidronate and zoledronate): a four-case report. J Oral Pathol Med 2005;34:613-7
13. Olson KB, Hellie CM, Pienta KJ. Osteonecrosis of jaw in patient with hormone-refractory prostate cancer treated with zoledronic acid. Urology 2005;66:658
14. Zervas K, Verrou E, Teleioudis Z, et al. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. Br J Haematol 2006;134:620-3
15. Sanna G, Preda L, Bruschini R, et al. Bisphosphonates and jaw osteonecrosis in patients with advanced breast cancer. Ann Oncol 2006;17:1512-6
16. Badros A, Weikel D, Salama A, et al. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 2006;24:945-52
17. Woo S-B, Hellstein JW, Kalmar JR. Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006;144:753-61
18. Migliorati CA, Siegel MA, Elting LS. Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonates treatment. Lancet Oncol 2006;7:508-14
19. Ruggiero SL, Fantasia J, Carlson E. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Pathol Oral Med 2006;102:433-41
20. Bilezikian JP. Osteonecrosis of the jaw-Do bisphosphonates pose a risk? N Engl J Med 2006;355:2278-81
21. Dunstan CR, Felsenberg D, Seibel MJ. Therapy insight: the risk and benefits of bisphosphonates for the treatment of tumorinduced bone disease. Nature Clin Pract Oncol 2007;4:42-55
22. Phal PM, Myall RW, Assael LA, et al. Imaging findings of bisphosphonate-associated osteonecrosis of the jaws. AJNR Am J Neuroradiol 2007;28:1139-45
23. Body J-J, Coleman R, Clezardin P, et al. International society of geriatric oncology (SIOG) clinical practice recommendation for the use of bisphosphonates in elderly patients. Eur J Cancer 2007;43:852-8
24. Weitzman R, Sauter N, Eriksen EF, et al. Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients-May 2006. Crit Rev Oncol Hematol 2007;62:148-52
25. Dannemann C, Gratz KW, Riener MO, et al. Jaw osteonecrosis related to bisphosphonates therapy. A severe secondary disorder. Bone 2007;40:828-34
26. Farrugia MC, Summerlin DJ, Krowiak E, et al. Osteonecrosis of the mandible or maxilla associated with the use of new generation bisphosphonates. Laringoscope 2006;116:115-20
27. Brooks JK, Gilson AJ, Sindler AG, et al. Osteonecrosis of the jaws associated with use of risendronate: report of 2 new cases. Oral Sur Oral Med Oral Pathol 2007;103:780-6
28. Nase JB, Suzuki JB. Osteonecrosis of the jaw and oral bisphosphonates treatment. J Am Dent Assoc 2006;137:1115-9
29. Senel FC, Tekin US, Durmus A, et al. Severe osteomyelitis of the mandible associated with the use of non-nitrogen-containing bisphosphonates (disodium clodronate): report of a case. J Oral Maxillofac Surg 2007;65:562-5
30. Montazeri AH, Erskine JG, McQuaker IG. Oral sodium clodronate induced osteonecrosis of the jaw in a patient with myeloma. Eur J Haematol 2007;79:69-71
31. Yarom N, Yahalom Y, Shoshani, et al. Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome. Osteoporos Int 2007;18(10):1363-70
32. Barmias A, Kastritis E, Bamia C, et al. Ostenecrosis of the jaws in cancer after treatment bisphosphonates: incidence and risk factors. J Clin Oncol 2005;23:8580-7
33. Wang EP, Kaban LB, Strewler GJ, et al. Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy. J Oral Maxillofac Surg 2007;65:1328-31
34. Wilkinson GS, Kuo Y-F, Freeman JL, et al. Intravenous bisphosphonate therapy and inflammatory conditions or surgery of the jaw: a population-based analysis. J Natl Cancer Inst 2007;99:1016-24
35. Miles AE. Phosphorus necrosis of the jaw: "phossy jaw". Br Dent J 1972;133:203-6
36. Hellstein JW, Marek CL. Bisphosphonate osteochemonecrosis (bis-phossy jaw): is this phossy jaw of the 21st century? J Oral Maxillofac Surg 2005;63:682-9
37. Wong JK, Wood RE, McClean M. Conservative management of osteoradionecrosis. Oral Surg Oral Med Oral Pathol 1997;84: 16-21
38. Epstein J, van der Meij E, McKenzie M, et al. Postradiation necrosis of the mandible: a long term follow-up study. Oral Surg Oral Med Oral Pathol 1997;83:657-62
39. Schwartz HC. Osteonecrosis of the jaws: a complication of cancer chemotherapy. Head Neck Surg 1982;4:251-3
40. Polizzotto MN, Cousins V, Schwarer AP. Bisphosphonate-associate osteonecrosis of the auditory canal. Br J Haematol 2006;132:114
41. Silverman SL, Maricic M. Recent developments in bisphosphonates therapy. Semin Arthritis Rheum 2007;37(1):1-12
42. Hewitt C, Farah CS. Bisphosphonate-related osteonecrosis of the jaws: a comprehensive review. J Oral Pathol Med 2007;36: 319-38
43. Reid IR, Bolland MJ. Is bisphosphonates-associated osteonecrosis of the jaw caused by soft tissue toxicity? Bone 2007;41: 318-20
44. Corso A, Varettoni M, Zappasodi P, et al. A different schedule of zolendronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma. Leukemia 2007;21: 1545-8
45. Kamaisi M, Regegev E, Yarom N, et al. Possible association between diabetes and bisphosphonates-related jaw osteonecrosis. J Clin Endocrinol Metab 2006;92:1172-5
46. Tada A, Senpuku H, Motozawa Y, et al. Association between commensal bacteria and opportunistic pathogens in the dental plaque of elderly individuals. Clin Microbiol Infect 2006;12: 776-81
47. Bullough P. Osteonecrosis and bone infarction. In: Bullogh P, editor Orthopaedic pathology. 4th ed. Edinburgh: Mosby; 2004. p. 347-62
48. Hansen T, Kunkel M, Weber A, et al. Osteonecrosis of the jaws in patients treated with bisphosphonates-histomorphologic analysis in comparison with infected osteoradionecrosis. J Oral Pathol Med 2006; 35:155-60
49. Whyte MP, Wenkert D, Clements KL, et al. Bisphosphonateinduced osteopetrosis. N Engl J Med 2003;349:457-63
50. Lew DP, Waldvogel FA. Osteomyelitis. Lancet 2004;364: 269-79
51. Greenspan SL, Rosen HN, Parker RA. Early changes in serum Ntelepeptide and C-telopeptide cross-linked collagen type 1 predict long-term response to alendronate therapy in elderly women. J Clin Endocrinol Metab 2000;85:3537-40
52. von Schewelov T, Carlsson A, Dahlberg L. Cross-linked N-telopeptide of type I collagen (NTx) in urine as predictor of periprosthetic osteolysis. J Orthop Res 2006;24:1342-8
53. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonates-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2007;65:369-76
54. Naveau A, Naveau B. Osteonecrosis of the jaw in patients taking bisphosphonates. Joint Bone Spine 2006;73:7-9
55. Van den Wyngaert T, Manon TU, Vermorken JB. Osteonecrosis of the jaw related to use of bisphosphonates. Curr Opin Oncol 2007;19:315-22
56. Marx RE, Sawatari Y, Fortin M, et al. Bisphosphonates-induced exposed bone of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005;63:1567-75
57. Thakkar SG, Isada C, Smith J, et al. Jaw complications associated with bisphosphonate use in patients with plasma cell dyscrasias. Med Oncol 2006;23:51-6
58. Pires FR, Mirando A, Cardoso ES, et al. Oral avascular bone necrosis associated with chemotherapy and bisphosphonate therapy. Oral Dis 2005;11:365-9
59. Montebugnoli L, Felicetti L, Gissi B, et al. Bisphosphonateassociated osteonecrosis can be controlled by nonsurgical management. Oral Surg Oral Med Oral Pathol 2007;104:473-7
60. Adornato MC, Morcos I, Rozanski J. The treatment of bisphosphonate-associated osteonecrosis of the jaws with bone resection and autologous platelet-derived growth factors. J Am Dent Assoc 2007;138:971-7
61. Freiberger JJ, Padilla-Burgos R, Chhoeu AH, et al. Hyperbaric oxygen treatment and bisphosphonates-induced osteonecrosis of the jaw: a case series. J Oral Maxillofac Surg 2007;65:1321-7
62. Agrillo A, Petrucci MT, Tedaldi M, et al. New therapeutic protocol in the treatment of avascular necrosis of the jaws. J Cranio Surg 2006;17:1080-3
63. Vescovi P, Merigo E, Meleti M, et al. Nd:YAG laser biostimulation of bisphosphonateassociated necrosis of the jawbone with and without surgical treatment. Br J Oral Maxillofac Surg 2007); (electronic version-in press)
64. Krueger CD, West PM, Sargent M, et al. Bisphosphonatesinduced osteonecrosis of the jaws. Ann Pharmacother 2007;41: 276-84